Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure

Rusty L. Montgomery, Thomas G. Hullinger, Hillary M. Semus, Brent A. Dickinson, Anita G. Seto, Joshua M. Lynch, Christianna Stack, Paul A. Latimer, Eric N. Olson, Eva Van Rooij

Research output: Contribution to journalArticle

379 Citations (Scopus)

Abstract

Background-: Diastolic dysfunction in response to hypertrophy is a major clinical syndrome with few therapeutic options. MicroRNAs act as negative regulators of gene expression by inhibiting translation or promoting degradation of target mRNAs. Previously, we reported that genetic deletion of the cardiac-specific miR-208a prevents pathological cardiac remodeling and upregulation of Myh7 in response to pressure overload. Whether this miRNA might contribute to diastolic dysfunction or other forms of heart disease is currently unknown. Methods and Results-: Here, we show that systemic delivery of an antisense oligonucleotide induces potent and sustained silencing of miR-208a in the heart. Therapeutic inhibition of miR-208a by subcutaneous delivery of antimiR-208a during hypertension-induced heart failure in Dahl hypertensive rats dose-dependently prevents pathological myosin switching and cardiac remodeling while improving cardiac function, overall health, and survival. Transcriptional profiling indicates that antimiR-208a evokes prominent effects on cardiac gene expression; plasma analysis indicates significant changes in circulating levels of miRNAs on antimiR-208a treatment. Conclusions-: These studies indicate the potential of oligonucleotide-based therapies for modulating cardiac miRNAs and validate miR-208 as a potent therapeutic target for the modulation of cardiac function and remodeling during heart disease progression.

Original languageEnglish (US)
Pages (from-to)1537-1547
Number of pages11
JournalCirculation
Volume124
Issue number14
DOIs
StatePublished - Oct 4 2011

Fingerprint

MicroRNAs
Heart Failure
Heart Diseases
Inbred Dahl Rats
Cardiac Myosins
Therapeutics
Gene Expression
Antisense Oligonucleotides
RNA Stability
Regulator Genes
Oligonucleotides
Hypertrophy
Disease Progression
Up-Regulation
Hypertension
Pressure
Health

Keywords

  • gene expression regulation
  • heart failure
  • hypertension
  • hypertrophy
  • microRNAs
  • molecular biology
  • ventricular remodeling

ASJC Scopus subject areas

  • Physiology (medical)
  • Cardiology and Cardiovascular Medicine

Cite this

Montgomery, R. L., Hullinger, T. G., Semus, H. M., Dickinson, B. A., Seto, A. G., Lynch, J. M., ... Van Rooij, E. (2011). Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation, 124(14), 1537-1547. https://doi.org/10.1161/CIRCULATIONAHA.111.030932

Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. / Montgomery, Rusty L.; Hullinger, Thomas G.; Semus, Hillary M.; Dickinson, Brent A.; Seto, Anita G.; Lynch, Joshua M.; Stack, Christianna; Latimer, Paul A.; Olson, Eric N.; Van Rooij, Eva.

In: Circulation, Vol. 124, No. 14, 04.10.2011, p. 1537-1547.

Research output: Contribution to journalArticle

Montgomery, RL, Hullinger, TG, Semus, HM, Dickinson, BA, Seto, AG, Lynch, JM, Stack, C, Latimer, PA, Olson, EN & Van Rooij, E 2011, 'Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure', Circulation, vol. 124, no. 14, pp. 1537-1547. https://doi.org/10.1161/CIRCULATIONAHA.111.030932
Montgomery RL, Hullinger TG, Semus HM, Dickinson BA, Seto AG, Lynch JM et al. Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. Circulation. 2011 Oct 4;124(14):1537-1547. https://doi.org/10.1161/CIRCULATIONAHA.111.030932
Montgomery, Rusty L. ; Hullinger, Thomas G. ; Semus, Hillary M. ; Dickinson, Brent A. ; Seto, Anita G. ; Lynch, Joshua M. ; Stack, Christianna ; Latimer, Paul A. ; Olson, Eric N. ; Van Rooij, Eva. / Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure. In: Circulation. 2011 ; Vol. 124, No. 14. pp. 1537-1547.
@article{ff49a28e037a4a21b3a324024018fe77,
title = "Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure",
abstract = "Background-: Diastolic dysfunction in response to hypertrophy is a major clinical syndrome with few therapeutic options. MicroRNAs act as negative regulators of gene expression by inhibiting translation or promoting degradation of target mRNAs. Previously, we reported that genetic deletion of the cardiac-specific miR-208a prevents pathological cardiac remodeling and upregulation of Myh7 in response to pressure overload. Whether this miRNA might contribute to diastolic dysfunction or other forms of heart disease is currently unknown. Methods and Results-: Here, we show that systemic delivery of an antisense oligonucleotide induces potent and sustained silencing of miR-208a in the heart. Therapeutic inhibition of miR-208a by subcutaneous delivery of antimiR-208a during hypertension-induced heart failure in Dahl hypertensive rats dose-dependently prevents pathological myosin switching and cardiac remodeling while improving cardiac function, overall health, and survival. Transcriptional profiling indicates that antimiR-208a evokes prominent effects on cardiac gene expression; plasma analysis indicates significant changes in circulating levels of miRNAs on antimiR-208a treatment. Conclusions-: These studies indicate the potential of oligonucleotide-based therapies for modulating cardiac miRNAs and validate miR-208 as a potent therapeutic target for the modulation of cardiac function and remodeling during heart disease progression.",
keywords = "gene expression regulation, heart failure, hypertension, hypertrophy, microRNAs, molecular biology, ventricular remodeling",
author = "Montgomery, {Rusty L.} and Hullinger, {Thomas G.} and Semus, {Hillary M.} and Dickinson, {Brent A.} and Seto, {Anita G.} and Lynch, {Joshua M.} and Christianna Stack and Latimer, {Paul A.} and Olson, {Eric N.} and {Van Rooij}, Eva",
year = "2011",
month = "10",
day = "4",
doi = "10.1161/CIRCULATIONAHA.111.030932",
language = "English (US)",
volume = "124",
pages = "1537--1547",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "14",

}

TY - JOUR

T1 - Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure

AU - Montgomery, Rusty L.

AU - Hullinger, Thomas G.

AU - Semus, Hillary M.

AU - Dickinson, Brent A.

AU - Seto, Anita G.

AU - Lynch, Joshua M.

AU - Stack, Christianna

AU - Latimer, Paul A.

AU - Olson, Eric N.

AU - Van Rooij, Eva

PY - 2011/10/4

Y1 - 2011/10/4

N2 - Background-: Diastolic dysfunction in response to hypertrophy is a major clinical syndrome with few therapeutic options. MicroRNAs act as negative regulators of gene expression by inhibiting translation or promoting degradation of target mRNAs. Previously, we reported that genetic deletion of the cardiac-specific miR-208a prevents pathological cardiac remodeling and upregulation of Myh7 in response to pressure overload. Whether this miRNA might contribute to diastolic dysfunction or other forms of heart disease is currently unknown. Methods and Results-: Here, we show that systemic delivery of an antisense oligonucleotide induces potent and sustained silencing of miR-208a in the heart. Therapeutic inhibition of miR-208a by subcutaneous delivery of antimiR-208a during hypertension-induced heart failure in Dahl hypertensive rats dose-dependently prevents pathological myosin switching and cardiac remodeling while improving cardiac function, overall health, and survival. Transcriptional profiling indicates that antimiR-208a evokes prominent effects on cardiac gene expression; plasma analysis indicates significant changes in circulating levels of miRNAs on antimiR-208a treatment. Conclusions-: These studies indicate the potential of oligonucleotide-based therapies for modulating cardiac miRNAs and validate miR-208 as a potent therapeutic target for the modulation of cardiac function and remodeling during heart disease progression.

AB - Background-: Diastolic dysfunction in response to hypertrophy is a major clinical syndrome with few therapeutic options. MicroRNAs act as negative regulators of gene expression by inhibiting translation or promoting degradation of target mRNAs. Previously, we reported that genetic deletion of the cardiac-specific miR-208a prevents pathological cardiac remodeling and upregulation of Myh7 in response to pressure overload. Whether this miRNA might contribute to diastolic dysfunction or other forms of heart disease is currently unknown. Methods and Results-: Here, we show that systemic delivery of an antisense oligonucleotide induces potent and sustained silencing of miR-208a in the heart. Therapeutic inhibition of miR-208a by subcutaneous delivery of antimiR-208a during hypertension-induced heart failure in Dahl hypertensive rats dose-dependently prevents pathological myosin switching and cardiac remodeling while improving cardiac function, overall health, and survival. Transcriptional profiling indicates that antimiR-208a evokes prominent effects on cardiac gene expression; plasma analysis indicates significant changes in circulating levels of miRNAs on antimiR-208a treatment. Conclusions-: These studies indicate the potential of oligonucleotide-based therapies for modulating cardiac miRNAs and validate miR-208 as a potent therapeutic target for the modulation of cardiac function and remodeling during heart disease progression.

KW - gene expression regulation

KW - heart failure

KW - hypertension

KW - hypertrophy

KW - microRNAs

KW - molecular biology

KW - ventricular remodeling

UR - http://www.scopus.com/inward/record.url?scp=80053567152&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053567152&partnerID=8YFLogxK

U2 - 10.1161/CIRCULATIONAHA.111.030932

DO - 10.1161/CIRCULATIONAHA.111.030932

M3 - Article

VL - 124

SP - 1537

EP - 1547

JO - Circulation

JF - Circulation

SN - 0009-7322

IS - 14

ER -